This week Achillion Pharmaceuticals announced that the FDA had given Fast Track designation to ACH-3102, a pan-genotypic second-generation NS5A inhibitor against HCV and being evaluated as part of an interferon-free regimen. The Fast Track designation was given on the basis of its potential to be developed in a once daily interferon-free fixed dose combination and its potent antiviral activity against HCV genotypes 1-6. It also has a low potential for drug-drug interactions and as a result has great potential to treat HCV patients which are co-infected with HIV, other comorbidities or pre-/post liver transplantation.
The chief executive of Achillion commented on the investigational drugs entry to the program – â€˜We are excited to leverage the superior profile of ACH-3102 in combination with our Phase 2 protease inhibitor, ACH-1625, as we seek to create an optimized, potentially best-in-class potent, well-tolerated, once-daily regimen to treat HCV'. On ACH-1625 some very promising data is also coming out, Phase 2 trials showed that after a 12 week study with 35 patients, 100% of the participants were virus free – including patients with IL28B genotype CT/TT, a very difficult strain to treat.
Maybe time to invest in some stocks? Particularly with some competition in the Hepatitis C market, this therapeutic could stand out! Indeed when ACH-1625 was compared to J&J's TMC435 the drug proved more effective.